The role of biologic markers in the diagnosis of Alzheimer's disease
2007; Wiley; Volume: 3; Issue: 4 Linguagem: Inglês
10.1016/j.jalz.2007.07.015
ISSN1552-5279
Autores Tópico(s)Cholinesterase and Neurodegenerative Diseases
ResumoAlzheimer's & DementiaVolume 3, Issue 4 p. 325-332 Review Article The role of biologic markers in the diagnosis of Alzheimer's disease Hyman M. Schipper, Corresponding Author Hyman M. Schipper [email protected] (514) 340-8260 | Fax: (514) 340-8925 Centre for Neurotranslational Research and Bloomfield Centre for Research in Aging, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada Corresponding author. Tel.: (514) 340-8260; Fax: (514) 340-8925. E-mail address: [email protected]Search for more papers by this author Hyman M. Schipper, Corresponding Author Hyman M. Schipper [email protected] (514) 340-8260 | Fax: (514) 340-8925 Centre for Neurotranslational Research and Bloomfield Centre for Research in Aging, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada Corresponding author. Tel.: (514) 340-8260; Fax: (514) 340-8925. E-mail address: [email protected]Search for more papers by this author First published: 18 September 2007 https://doi.org/10.1016/j.jalz.2007.07.015Citations: 11Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References [1]W.E. Klunk. Biological markers of Alzheimer's disease. Neurobiol Aging. 19: 1998; 145–147 [2]R.A. Frank, D. Galasko, H. Hampel, J. Hardy, M.J. de Leon, P.D. Mehta, et al. Biological markers for therapeutic trials in Alzheimer's disease: proceedings of the biological markers working group—NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging. 24: 2003; 521–536 [3]T. Iwatsubo. Amyloid beta protein in plasma as a diagnostic marker for Alzheimer's disease. Neurobiol Aging. 19: 1998; 161–163 [4]K. Blennow, H. Hampel. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2: 2003; 605–613 [5]M. Shoji. Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness. Front Biosci. 7: 2002; 997–1006 [6]A. Olsson, K. Hoglund, M. Sjogren, N. Andreasen, L. Minthon, L. Lannfelt, et al. Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol. 183: 2003; 74–80 [7]P.D. Mehta, T. Pirttila, S.P. Mehta, E.A. Sersen, P.S. Aisen, H.M. Wisniewski. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol. 57: 2000; 100–105 [8]A. Tamaoka, T. Fukushima, N. Sawamura, K. Ishikawa, E. Oguni, Y. Komatsuzaki, et al. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. J Neurol Sci. 141: 1996; 65–68 [9]T. Sunderland, G. Linker, N. Mirza, K.T. Putnam, D.L. Friedman, L.H. Kimmel, et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. 289: 2003; 2094–2103 [10]F. Hulstaert, K. Blennow, A. Ivanoiu, H.C. Schoonderwaldt, M. Riemenschneider, P.P. De Deyn, et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology. 52: 1999; 1555–1562 [11]B. Mollenhauer, L. Cepek, M. Bibl, J. Wiltfang, W.J. Schulz-Schaeffer, B. Ciesielczyk, et al. Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord. 19: 2005; 164–170 [12]C.M. Clark, S. Xie, J. Chittams, D. Ewbank, E. Peskind, D. Galasko, et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol. 60: 2003; 1696–1702 [13]E. Gomez-Tortosa, I. Gonzalo, S. Fanjul, M.J. Sainz, S. Cantarero, C. Cemillan, et al. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Arch Neurol. 60: 2003; 1218–1222 [14]M. Otto, H. Esselmann, W. Schulz-Shaeffer, M. Neumann, A. Schroter, P. Ratzka, et al. Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology. 54: 2000; 1099–1102 [15]B. Holmberg, B. Johnels, K. Blennow, L. Rosengren. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord. 18: 2003; 186–190 [16]M. Sjogren, N. Andreasen, K. Blennow. Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers. Clin Chim Acta. 332: 2003; 1–10 [17]P. Lewczuk, H. Esselmann, T.W. Groemer, M. Bibl, J.M. Maler, P. Steinacker, et al. Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease. Biol Psychiatry. 55: 2004; 524–530 [18]M. Maruyama, T. Matsui, H. Tanji, M. Nemoto, N. Tomita, M. Ootsuki, et al. Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways. Arch Neurol. 61: 2004; 716–720 [19]N. Andreasen, L. Minthon, A. Clarberg, P. Davidsson, J. Gottfries, E. Vanmechelen, et al. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology. 53: 1999; 1488–1494 [20]A.J. Green, R.J. Harvey, E.J. Thompson, M.N. Rossor. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci Lett. 259: 1999; 133–135 [21]C. Hesse, L. Rosengren, E. Vanmechelen, H. Vanderstichele, C. Jensen, P. Davidsson, et al. Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J Alzheimers Dis. 2: 2000; 199–206 [22]M. Grossman, J. Farmer, S. Leight, M. Work, P. Moore, V. Van Deerlin, et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann Neurol. 57: 2005; 721–729 [23]J. Leszek, K. Malyszczak, B. Janicka, A. Kiejna, A. Wiak. Total tau in cerebrospinal fluid differentiates Alzheimer's disease from vascular dementia. Med Sci Monit. 9: 2003; CR484–CR488 [24]H. Hampel, K. Buerger, R. Zinkowski, S.J. Teipel, A. Goernitz, N. Andreasen, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry. 61: 2004; 95–102 [25]P. Lewczuk, H. Esselmann, M. Bibl, G. Beck, J.M. Maler, M. Otto, et al. Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature. J Mol Neurosci. 23: 2004; 115–122 [26]E. Vanmechelen, H. Vanderstichele, P. Davidsson, E. Van Kerschaver, B. Van Der Perre, M. Sjogren, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett. 285: 2000; 49–52 [27]N.S. Schoonenboom, Y.A. Pijnenburg, C. Mulder, S.M. Rosso, E.J. Van Elk, G.J. Van Kamp, et al. Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology. 62: 2004; 1580–1584 [28]A. Kurz, M. Riemenschneider, A. Wallin. Potential biological markers for cerebrovascular disease. Int Psychogeriatr. 15 (Suppl 1): 2003; 89–97 [29]L. Parnetti, A. Lanari, S. Amici, V. Gallai, E. Vanmechelen, F. Hulstaert. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies: Phospho-Tau International Study Group. Neurol Sci. 22: 2001; 77–78 [30]K. Blennow, A. Wallin, H. Agren, C. Spenger, J. Siegfried, E. Vanmechelen. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol. 26: 1995; 231–245 [31]C. Hesse, L. Rosengren, N. Andreasen, P. Davidsson, H. Vanderstichele, E. Vanmechelen, et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett. 297: 2001; 187–190 [32]P. Schonknecht, A. Hempel, A. Hunt, U. Seidl, M. Volkmann, J. Pantel, et al. Cerebrospinal fluid tau protein levels in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 253: 2003; 100–102 [33]C.A. Goodall, M.W. Head, D. Everington, J.W. Ironside, R.S. Knight, A.J. Green. Raised CSF phospho-tau concentrations in variant Creutzfeldt-Jakob disease: diagnostic and pathological implications. J Neurol Neurosurg Psychiatry. 77: 2006; 89–91 [34]M. Riemenschneider, S. Wagenpfeil, H. Vanderstichele, M. Otto, J. Wiltfang, H. Kretzschmar, et al. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry. 8: 2003; 343–347 [35]P. Schonknecht, J. Pantel, A. Hunt, M. Volkmann, K. Buerger, H. Hampel, et al. Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease. Neurosci Lett. 339: 2003; 172–174 [36]K. Buerger, S.J. Teipel, R. Zinkowski, K. Blennow, H. Arai, R. Engel, et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 59: 2002; 627–629 [37]H. Arai, K. Ishiguro, H. Ohno, M. Moriyama, N. Itoh, N. Okamura, et al. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol. 166: 2000; 201–203 [38]M.J. de Leon, S. DeSanti, R. Zinkowski, P.D. Mehta, D. Pratico, S. Segal, et al. MRI and CSF studies in the early diagnosis of Alzheimer's disease. J Intern Med. 256: 2004; 205–223 [39]K. Blennow. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx. 1: 2004; 213–225 [40]L.O. Wahlund, K. Blennow. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett. 339: 2003; 99–102 [41]S. Ganzer, S. Arlt, V. Schoder, C. Buhmann, E.M. Mandelkow, U. Finckh, et al. CSF-tau, CSF-Abeta1-42, ApoE-genotype and clinical parameters in the diagnosis of Alzheimer's disease: combination of CSF-tau and MMSE yields highest sensitivity and specificity. J Neural Transm. 110: 2003; 1149–1160 [42]M. Riemenschneider, N. Lautenschlager, S. Wagenpfeil, J. Diehl, A. Drzezga, A. Kurz. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol. 59: 2002; 1729–1734 [43]H. Hampel, S.J. Teipel, T. Fuchsberger, N. Andreasen, J. Wiltfang, M. Otto, et al. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry. 9: 2004; 705–710 [44]S.K. Herukka, M. Hallikainen, H. Soininen, T. Pirttila. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology. 64: 2005; 1294–1297 [45]A. Ivanoiu, C.J. Sindic. Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination. Neurocase. 11: 2005; 32–39 [46]W.E. Klunk. Blood and CSF biomarkers for AD revisited: what's new, what's good, and is this where we should be looking? Neurobiol Aging. 23: 2002; 517–519, discussion 521–2 [47]E.R. Peskind, R. Riekse, J.F. Quinn, J. Kaye, C.M. Clark, M.R. Farlow, et al. Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord. 19: 2005; 220–225 [48]S.M. De La Monte, J.R. Wands. The AD7c-NTP neuronal thread protein biomarker for detecting Alzheimer's disease. J Alzheimers Dis. 3: 2001; 345–353 [49]H. Chertkow, H. Bergman, H.M. Schipper, S. Gauthier, R. Bouchard, S. Fontaine, et al. Assessment of suspected dementia. Can J Neurol Sci. 28 (Suppl 1): 2001; S28–S41 [50]M.L. Kennard, H. Feldman, T. Yamada, W.A. Jefferies. Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease. Nat Med. 2: 1996; 1230–1235 [51]D.K. Kim, M.Y. Seo, S.W. Lim, S. Kim, J.W. Kim, B.J. Carroll, et al. Serum melanotransferrin, p97 as a biochemical marker of Alzheimer's disease. Neuropsychopharmacology. 25: 2001; 84–90 [52]R.R. Desrosiers, Y. Bertrand, Q.T. Nguyen, M. Demeule, R. Gabathuler, M.L. Kennard, et al. Expression of melanotransferrin isoforms in human serum: relevance to Alzheimer's disease. Biochem J. 374 (Pt 2): 2003; 463–471 [53]M. Di Luca, L. Pastorino, A. Bianchetti, J. Perez, L.A. Vignolo, G.L. Lenzi, et al. Differential level of platelet amyloid beta precursor protein isoforms: an early marker for Alzheimer disease. Arch Neurol. 55: 1998; 1195–1200 [54]M. Di Luca, L. Pastorino, F. Cattabeni, R. Zanardi, S. Scarone, G. Racagni, et al. Abnormal pattern of platelet APP isoforms in Alzheimer disease and Down syndrome. Arch Neurol. 53: 1996; 1162–1166 [55]R.N. Rosenberg, F. Baskin, J.A. Fosmire, R. Risser, P. Adams, D. Svetlik, et al. Altered amyloid protein processing in platelets of patients with Alzheimer disease. Arch Neurol. 54: 1997; 139–144 [56]A. Padovani, L. Pastorino, B. Borroni, F. Colciaghi, L. Rozzini, R. Monastero, et al. Amyloid precursor protein in platelets: a peripheral marker for the diagnosis of sporadic AD. Neurology. 57: 2001; 2243–2248 [57]F. Baskin, R.N. Rosenberg, L. Iyer, L. Hynan, C.M. Cullum. Platelet APP isoform ratios correlate with declining cognition in AD. Neurology. 54: 2000; 1907–1909 [58]B. Borroni, F. Colciaghi, S. Archetti, E. Marcello, L. Caimi, M. Di Luca, et al. Predicting cognitive decline in Alzheimer disease: Role of platelet amyloid precursor protein. Alzheimer Dis Assoc Disord 18: 2004; 32–34 [59]B. Borroni, F. Colciaghi, C. Caltagirone, L. Rozzini, L. Broglio, F. Cattabeni, et al. Platelet amyloid precursor protein abnormalities in mild cognitive impairment predict conversion to dementia of Alzheimer type: a 2-year follow-up study. Arch Neurol. 60: 2003; 1740–1744 [60]A. Padovani, B. Borroni, F. Colciaghi, C. Pettenati, E. Cottini, C. Agosti, et al. Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease. Arch Neurol. 59: 2002; 71–75 [61]B. Borroni, F. Colciaghi, L. Pastorino, C. Pettenati, E. Cottini, L. Rozzini, et al. Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment. Arch Neurol. 58: 2001; 442–446 [62]H.C. Liu, C.W. Chi, S.Y. Ko, H.C. Wang, C.J. Hong, K.N. Lin, et al. Cholinesterase inhibitor affects the amyloid precursor protein isoforms in patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 19: 2005; 345–348 [63]M. Zimmermann, B. Borroni, F. Cattabeni, A. Padovani, M. Di Luca. Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients. Neurobiol Dis. 19: 2005; 237–242 [64]H.M. Schipper. Brain iron deposition and the free radical-mitochondrial theory of ageing. Ageing Res Rev. 3: 2004; 265–301 [65]W.R. Markesbery, J.M. Carney. Oxidative alterations in Alzheimer's disease. Brain Pathol. 9: 1999; 133–146 [66]D. Galasko. Biological markers and the treatment of Alzheimer's disease. J Mol Neurosci. 17: 2001; 119–125 [67]R.B. Maccioni, M. Lavados, C.B. Maccioni, A. Mendoza-Naranjo. Biological markers of Alzheimer's disease and mild cognitive impairment. Curr Alzheimer Res. 1: 2004; 307–314 [68]E.E. Tuppo, L.J. Forman, B.W. Spur, R.E. Chan-Ting, A. Chopra, T.A. Cavalieri. Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer's disease. Brain Res Bull. 54: 2001; 565–568 [69]D. Pratico, M.Y.L. V, J.Q. Trojanowski, J. Rokach, G.A. Fitzgerald. Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. Faseb J. 12: 1998; 1777–1783 [70]D. Pratico, C.M. Clark, F. Liun, J. Rokach, V.Y. Lee, J.Q. Trojanowski. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol. 59: 2002; 972–976 [71]T.J. Montine, J.A. Kaye, K.S. Montine, L. McFarland, J.D. Morrow, J.F. Quinn. Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. Arch Pathol Lab Med. 125: 2001; 510–512 [72]T.J. Montine, J.F. Quinn, D. Milatovic, L.C. Silbert, T. Dang, S. Sanchez, et al. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol. 52: 2002; 175–179 [73]A. Greco, L. Minghetti, G. Levi. Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases. Neurochem Res. 25: 2000; 1357–1364 [74]H.M. Schipper, H. Chertkow, K. Mehindate, D. Frankel, C. Melmed, H. Bergman. Evaluation of heme oxygenase-1 as a systemic biological marker of sporadic AD. Neurology. 54: 2000; 1297–1304 [75]K. Ishizuka, T. Kimura, J. Yoshitake, T. Akaike, M. Shono, J. Takamatsu, et al. Possible assessment for antioxidant capacity in Alzheimer's disease by measuring lymphocyte heme oxygenase-1 expression with real-time RT-PCR. Ann N Y Acad Sci. 977: 2002; 173–178 [76]H.M. Schipper, Y. Mawal, H. Chertkow, H. Bergman. Blood HO-1 mRNA in AD and MCI. Neurology. 57: 2001; 2142–2143 [77]O.C. Maes, S. Kravitz, Y. Mawal, H. Su, A. Liberman, K. Mehindate, et al. Characterization of alpha(1)-antitrypsin as a heme oxygenase-1 suppressor in Alzheimer plasma. Neurobiol Dis. 24: 2006; 89–100 [78]H.M. Schipper, S. Cissé, E.G. Stopa. Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain. Ann Neurol. 37: 1995; 758–768 [79]D.H. Small. Alzheimer's disease biomarkers: their value in diagnosis and clinical trials. Front Biosci. 7: 2002; 986–988 [80]M.C. Irizarry. Biomarkers of Alzheimer disease in plasma. NeuroRx. 1: 2004; 226–234 [81]P. Davidsson, M. Sjogren. The use of proteomics in biomarker discovery in neurodegenerative diseases. Dis Markers. 21: 2005; 81–92 [82]L. Ho, N. Sharma, L. Blackman, E. Festa, G. Reddy, G.M. Pasinetti. From proteomics to biomarker discovery in Alzheimer's disease. Brain Res Brain Res Rev. 48: 2005; 360–369 [83]H. Wada. Analyses of serum concentrations of apolipoproteins in the demented elderly. Intern Med. 39: 2000; 220–222 [84]M. Meli, C. Perier, C. Ferron, F. Parssegny, C. Denis, R. Gonthier, et al. Serum pentosidine as an indicator of Alzheimer's disease. J Alzheimers Dis. 4: 2002; 93–96 [85]C. Mulder, P. Scheltens, J.J. Visser, G.J. van Kamp, R.B. Schutgens. Genetic and biochemical markers for Alzheimer's disease: recent developments. Ann Clin Biochem. 37 (Pt 5): 2000; 593–607 [86]A. Padovani, B. Borroni, M. Di Luca. Advances on biological markers in early diagnosis of Alzheimer disease. Adv Clin Chem. 39: 2005; 107–129 [87]L.H. Choe, M.J. Dutt, N. Relkin, K.H. Lee. Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease. Electrophoresis. 23: 2002; 2247–2251 [88]H.-L. Yu, H.M. Chertkow, H. Bergman, H.M. Schipper. Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma. Proteomics. 3: 2003; 2240–2248 [89]J.Q. Trojanowski, M.-Y. Lee. Commentary on “Diagnosis of Alzheimer's disease: Two decades of progress”: Alzheimer's disease research—new opportunities for early diagnosis and drug discovery. Alz Dement. 1: 2005; 119–120 [90]J.C. Morris, A. Kimberly, K. Quaid, D.M. Holtzman, K. Kantarci, J. Kaye, et al. Role of biomarkers in studies of presymptomatic Alzheimer's disease. Alz Dement. 1: 2005; 145–151 Citing Literature Volume3, Issue4October 2007Pages 325-332 ReferencesRelatedInformation
Referência(s)